SMAD3 and chronic kidney disease: Thus, the imbalance between Smad3 and Smad7 signaling may be a key mechanism in fibrogenesis and rebalancing this pathway by overexpressing Smad7 and inactivating Smad3 may represent as a better therapeutic strategy for CKD.